603387 Getein Biotech,Inc
- 8.87
- -0.08-0.89%
Getein Biotech,Inc News
Basic Egg Biology (603387): Multi-production line layout and platform-based construction first take shape
Basal Egg Biology (603387): Various product lines have returned to a rapid growth channel, and the results for the first quarter of this year exceeded expectations
Basal Egg Biology (603387): Performance picked up, and the market for new products reacted positively
Basic Egg Biology (603387): As the impact of the epidemic gradually weakened, sales gradually picked up, and new products were introduced in an orderly manner to bring new impetus to the market
Basal Egg Biology (603387): Leading domestic POCT companies actively lay out major tests
Basic egg biology (603387): benefit from the demand of agency business, Q3 revenue doubles, growth, new product promotion will bring more room for growth in the future.
Dynamic review of key egg biology (603387) company: the performance is in line with the expected Q2 revenue month-on-month improvement
Basic egg biology (603387): Q2 hospital-end demand gradually resumes and new products are introduced to the market will drive performance growth
Basic egg biology (603387): POCT helps to promote the strategy of biochemical luminescence in grass-roots medical care.
Comments on the annual report of basic egg biology (603387) 2018: it is worth looking forward to for POCT to maintain high growth and multi-faceted layout.
Key egg biology (603387) annual report review report: performance in line with expectations of new products to promote long-term development
基蛋生物(603387)深度报告：心血管类POCT领先企业 “试剂+生物原料+仪器”协同发展助高成长
基蛋生物(603387)季报点评：费用拖累业绩 三季度略低预期
基蛋生物(603387)三季报点评：业绩增长稳健 在印度设立子公司完善海外营销网络建设
基蛋生物(603387)季报点评：三季度收入增速下滑 持续加码研发投入
基蛋生物(603387)中报点评：全自动仪器快速上量 驱动收入增速超预期
基蛋生物(603387)半年报点评：业绩延续高增长 新品值得期待
基蛋生物(603387)中报点评：业绩符合预期 心血管POCT业务延续高增长趋势
基蛋生物(603387)中报点评：业绩快速增长 看好公司发展
基蛋生物(603387)2018年中报点评：业绩表现靓丽 不断丰富仪器产品线和检测项目
Analysis
Price Target
No Data
No Data